Skip to Content

Inamrinone Pregnancy and Breastfeeding Warnings

Inamrinone is also known as: Inocor I V

Inamrinone Pregnancy Warnings

Limited animal data revealed skeletal and gross external malformations in rabbits after administration of inamrinone dosages approximately one to three times the maximum recommended human dosage (on a per kg basis). Other animal (rabbit and rat) studies failed to corroborate these findings. A single case in which an inamrinone dosage regimen of 0.5 mg per kg, then 2 mcg per kg per minute was administered to a pregnant woman (18 weeks) with bacterial endocarditis and heart failure has been reported. No adverse fetal effects were observed. However, due to her serious underlying disease, the woman spontaneously aborted 11 weeks after discontinuation of inamrinone.

Inamrinone has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity. There are no controlled data in human pregnancy. A case report of inamrinone use in a pregnant woman failed to reveal fetal toxicity, however, the pregnancy terminated in a spontaneous abortion several weeks following discontinuation of inamrinone. Inamrinone should be used during pregnancy only when benefit outweighs risk.

See references

Inamrinone Breastfeeding Warnings

There are no data on the excretion of inamrinone into human milk. The manufacturer recommends that caution be used when administering inamrinone to nursing women.

See references

References for pregnancy information

  1. "Product Information. Inocor (inamrinone)." Sanofi Winthrop Pharmaceuticals, New York, NY.
  2. Jelsema RD, Bhatia RK, Ganguly S "Use of intravenous amrinone in the short-term management of refractory heart failure in pregnancy." Obstet Gynecol 78 (1991): 935-6
  3. Fishburne JI, Dormer KJ, Payne GG, Gill PS, Ashrafzadeh AR, Rossavik IK "Effects of amrinone and dopamine on uterine blood flow and vascular responses in the gravid baboon." Am J Obstet Gynecol 158 (1988): 829-37

References for breastfeeding information

  1. "Product Information. Inocor (inamrinone)." Sanofi Winthrop Pharmaceuticals, New York, NY.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.